Pregabalin Capsule
Product Images NDC 71610-845

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-845). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 150 mg (71610 0845 30)

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

This text provides a formula for calculating the estimated creatinine clearance (CLCr) based on age, weight, and serum creatinine levels. The formula takes into account the patient's age, weight, and serum creatinine level. Additionally, the formula adjusts the result if the patient is female by multiplying by 0.85.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This text provides information on the percentage of patients who improved with different treatments including Pregabalin at varying doses and a placebo. It also shows the percent improvement in pain from baseline.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This information provides a graph showing the percentage of patients who improved their pain levels from baseline when taking Pregabalin 100 mg three times a day compared to a placebo. The graph shows a significant improvement in pain as the dosage increases, with 100% of patients experiencing improvement.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This information provides data on the percentage of patients who experienced pain relief with different doses of pregabalin compared to a placebo. The chart displays the level of improvement in pain from baseline for different dosage regimens of pregabalin, including 75 mg, 150 mg and 300 mg taken twice a day. The data shows a trend of increased pain relief with higher doses of pregabalin.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This text provides information on the percentage of patients improved with pregabalin at different doses compared to a placebo. It also shows the percentage improvement in pain from baseline at various levels. This data can be useful for evaluating the effectiveness of various doses of pregabalin in managing pain.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This text provides information on the percent of patients improved when treated with different doses of pregabalin and a placebo. The improvement in pain from baseline is shown progressively from more than 10% to over 90%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This data appears to be related to a study evaluating different doses of a medication, with responder rates indicated for each dosage level. The percentages range from 9% to 60%, with some doses showing statistically significant differences compared to a placebo. The study includes different dosing schedules, such as BID (twice a day) and TID (three times a day). The higher dosages, like 600 mg/day, seem to have higher responder rates.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This description shows a list of p-values and corresponding doses in milligrams per day, possibly related to a study or experiment with a placebo group. The values indicate strong statistical significance as the p-values are all below 0.0001. The data might be further organized based on the doses and their effects.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This chart shows the percentage of patients who experienced improvement in pain levels when taking different doses of Pregabalin compared to a placebo. The doses of Pregabalin ranged from 300mg to 600mg daily. The chart displays the percentage of patients who saw improvement in pain levels above certain thresholds ranging from more than 20% to 100%.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This text shows a table with estimated percentages for "Subjects without LIR" across various levels. The data suggests the effects of Pregabalin compared to Placebo over a period of days ranging from 80 to 180. The percentage of subjects without LIR is not consistently mentioned for all levels.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This text provides information on the percentage of subjects who improved from baseline to week 12 for both Pregabalin and Placebo in a study. The data is presented in a graphical format showing the percentage of improvement at various intervals from greater than 0% to 100%.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This information appears to be showing the percentage of subjects that improved with Pregabalin compared to Placebo from baseline to week 16 using the BOCF method. The data is presented in ranges, such as >10%, >20%, and so on, up to >80%. The table indicates the percentage of subjects in each category that showed improvement.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.